Published in Pediatr Cardiol on July 03, 2013
Single Low-Density Lipoprotein Apheresis Does Not Improve Vascular Endothelial Function in Chronically Treated Hypercholesterolemic Patients. Int J Vasc Med (2016) 0.78
Aerobic exercise training protects against endothelial dysfunction by increasing nitric oxide and hydrogen peroxide production in LDL receptor-deficient mice. J Transl Med (2016) 0.75
Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation (2007) 11.95
Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol (2010) 9.44
Role of endothelial dysfunction in atherosclerosis. Circulation (2004) 5.77
Noninvasive assessment of subclinical atherosclerosis in children and adolescents: recommendations for standard assessment for clinical research: a scientific statement from the American Heart Association. Hypertension (2009) 3.22
Endothelial function predicts progression of carotid intima-media thickness. Circulation (2009) 2.30
Association of small artery elasticity with incident cardiovascular disease in older adults: the multi-ethnic study of atherosclerosis. Am J Epidemiol (2011) 2.01
Measurement of arterial wall thickness as a surrogate marker for atherosclerosis. Circulation (2004) 1.98
Arterial intima-media thickness in children heterozygous for familial hypercholesterolaemia. Lancet (2004) 1.84
Impairment of endothelium-dependent dilation is an early event in children with familial hypercholesterolemia and is related to the lipoprotein(a) level. J Clin Invest (1994) 1.72
Flow-mediated dilation and cardiovascular event prediction: does nitric oxide matter? Hypertension (2011) 1.69
Endothelial function, but not carotid intima-media thickness, is affected early in menopause and is associated with severity of hot flushes. J Clin Endocrinol Metab (2010) 1.32
Arterial compliance to stratify cardiovascular risk: more precision in therapeutic decision making. Am J Hypertens (2001) 1.02
Arterial mechanical changes in children with familial hypercholesterolemia. Arterioscler Thromb Vasc Biol (2000) 1.01
Pulse wave velocity and augmentation index, but not intima-media thickness, are early indicators of vascular damage in hypercholesterolemic children. Eur J Clin Invest (2010) 0.99
Arterial endothelial function and wall thickness in familial hypercholesterolemia and familial combined hyperlipidemia and the effect of statins. A systematic review and meta-analysis. Atherosclerosis (2010) 0.98
Changes in vascular function and structure in juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) (2011) 0.95
Predictors of endothelial dysfunction in young women with polycystic ovary syndrome. J Clin Endocrinol Metab (2005) 0.95
Management of familial hypercholesterolemia in children and young adults: consensus paper developed by a panel of lipidologists, cardiologists, paediatricians, nutritionists, gastroenterologists, general practitioners and a patient organization. Atherosclerosis (2011) 0.94
Noninvasive assessment of arterial stiffness and risk of atherosclerotic events in children. Pediatr Res (2005) 0.93
Family history of cardiovascular events and endothelial dysfunction in children with familial hypercholesterolemia. Atherosclerosis (2002) 0.89
One-month therapy with simvastatin restores endothelial function in hypercholesterolemic children and adolescents. Pediatr Cardiol (2007) 0.82
Predictors of large and small artery elasticity in healthy subjects from 9 to 89 years old. Am J Hypertens (2011) 0.81
Characterization and geographic distribution of the low density lipoprotein receptor (LDLR) gene mutations in northwestern Greece. Hum Mutat (2001) 0.77
Modelling the role of dietary habits and eating behaviours on the development of acute coronary syndrome or stroke: aims, design, and validation properties of a case-control study. Cardiol Res Pract (2010) 0.77
Familial hypercholesterolemia in children. Curr Opin Lipidol (2004) 0.77
Impact of low-density lipoprotein receptor mutational class on carotid atherosclerosis in patients with familial hypercholesterolemia. Atherosclerosis (2009) 0.77
Small arterial elasticity predicts the extent of coronary artery disease: Relationship with serum uric acid. Atherosclerosis (2008) 0.76
A review of drug-induced hyponatremia. Am J Kidney Dis (2008) 2.97
Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med (2014) 2.90
The effect of Mediterranean diet on metabolic syndrome and its components: a meta-analysis of 50 studies and 534,906 individuals. J Am Coll Cardiol (2011) 2.62
Statin therapy and outcome after ischemic stroke: systematic review and meta-analysis of observational studies and randomized trials. Stroke (2013) 2.53
Angiographic stent thrombosis after routine use of drug-eluting stents in ST-segment elevation myocardial infarction: the importance of thrombus burden. J Am Coll Cardiol (2007) 2.50
Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes. Circulation (2004) 1.91
Therapeutic approach in patients with dysnatraemias. Nephrol Dial Transplant (2006) 1.90
Association of Helicobacter pylori infection with cardiovascular disease--is it just a myth? Eur J Intern Med (2010) 1.67
Centralized Pan-European survey on the under-treatment of hypercholesterolaemia (CEPHEUS): overall findings from eight countries. Curr Med Res Opin (2010) 1.56
Benign migratory glossitis or geographic tongue: an enigmatic oral lesion. Am J Med (2002) 1.49
ANGIOCARE: an automated system for fast three-dimensional coronary reconstruction by integrating angiographic and intracoronary ultrasound data. Catheter Cardiovasc Interv (2008) 1.46
Platelets as predictors of vascular risk: is there a practical index of platelet activity? Clin Appl Thromb Hemost (2003) 1.45
Enoxaparin versus tinzaparin in non-ST-segment elevation acute coronary syndromes: the EVET trial. Am Heart J (2003) 1.43
Enoxaparin versus tinzaparin in non-ST-segment elevation acute coronary syndromes: results of the enoxaparin versus tinzaparin (EVET) trial at 6 months. Am Heart J (2005) 1.41
Unexplained hypertransaminasaemia: clue to diagnosis of Addison's disease. Eur J Gastroenterol Hepatol (2002) 1.40
Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma. Clin Chem (2005) 1.40
The effect of simvastatin alone versus simvastatin plus ezetimibe on the concentration of small dense low-density lipoprotein cholesterol in subjects with primary hypercholesterolemia. Curr Med Res Opin (2011) 1.39
Endothelial function, but not carotid intima-media thickness, is affected early in menopause and is associated with severity of hot flushes. J Clin Endocrinol Metab (2010) 1.32
Determinants of vascular function in patients with type 2 diabetes. Cardiovasc Diabetol (2012) 1.24
Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study. Nephrol Dial Transplant (2006) 1.24
A review of drug-induced hypocalcemia. J Bone Miner Metab (2009) 1.23
The prevalence of the metabolic syndrome using the National Cholesterol Educational Program and International Diabetes Federation definitions. Curr Med Res Opin (2005) 1.22
Apolipoprotein E and renal disease. Am J Kidney Dis (2004) 1.20
The effect of shear stress on neointimal response following sirolimus- and paclitaxel-eluting stent implantation compared with bare-metal stents in humans. JACC Cardiovasc Interv (2010) 1.20
Association of interleukin-6 (IL-6)-174G/C gene polymorphism with cardiovascular disease in patients with rheumatoid arthritis: the role of obesity and smoking. Atherosclerosis (2008) 1.19
Impaired endothelial function in young women with premature ovarian failure: normalization with hormone therapy. J Clin Endocrinol Metab (2004) 1.19
Rosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemia. Am J Cardiovasc Drugs (2010) 1.18
An overview of the extra-lipid effects of rosuvastatin. J Cardiovasc Pharmacol Ther (2008) 1.16
Novel roles of vitamin D in disease: what is new in 2011? Eur J Intern Med (2011) 1.14
LDL cholesterol estimation in patients with the metabolic syndrome. Lipids Health Dis (2006) 1.12
Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Am J Kidney Dis (2004) 1.11
Prediabetes: to treat or not to treat? Eur J Pharmacol (2011) 1.11
A methodology for the automated creation of fuzzy expert systems for ischaemic and arrhythmic beat classification based on a set of rules obtained by a decision tree. Artif Intell Med (2007) 1.09
Dyslipidemia associated with chronic kidney disease. Open Cardiovasc Med J (2011) 1.06
Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2. Arterioscler Thromb Vasc Biol (2007) 1.05
Hsp70 translocates to the nuclei and nucleoli, binds to XRCC1 and PARP-1, and protects HeLa cells from single-strand DNA breaks. Cell Stress Chaperones (2008) 1.05
Acute pancreatitis possibly associated with combined salicylate and atorvastatin therapy. JOP (2003) 1.04
Concentration and relative distribution of low-density lipoprotein subfractions in patients with metabolic syndrome defined according to the National Cholesterol Education Program criteria. Metabolism (2006) 1.02
Awareness, treatment and control of the metabolic syndrome and its components: a multicentre Greek study. Hellenic J Cardiol (2006) 1.02
Automated diagnosis of coronary artery disease based on data mining and fuzzy modeling. IEEE Trans Inf Technol Biomed (2008) 1.02
Clinical importance and therapeutic modulation of small dense low-density lipoprotein particles. Expert Opin Biol Ther (2007) 1.01
"European panel on low density lipoprotein (LDL) subclasses": a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses. Curr Vasc Pharmacol (2011) 1.00
Altered distribution of platelet-activating factor- acetylhydrolase activity between LDL and HDL as a function of the severity of hypercholesterolemia. J Lipid Res (2002) 1.00
Early vascular benefits of statin therapy. Curr Med Res Opin (2003) 0.99
Pioglitazone vs glimepiride: Differential effects on vascular endothelial function in patients with type 2 diabetes. Atherosclerosis (2008) 0.98
Severe hypocholesterolemia with reduced serum lipoprotein(a) in a patient with visceral leishmaniasis. Ann Clin Lab Sci (2002) 0.98
Prevalence of atherosclerotic vascular disease among subjects with the metabolic syndrome with or without diabetes mellitus: the METS-GREECE Multicentre Study. Curr Med Res Opin (2004) 0.97
Baseline cholesterol is associated with the response to antiviral therapy in chronic hepatitis C. J Gastroenterol Hepatol (2007) 0.97
Safety and impact on cardiovascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: a post hoc analysis of the randomised ATTEMPT study. Arch Med Sci (2011) 0.96
Hybrid intravascular imaging: current applications and prospective potential in the study of coronary atherosclerosis. J Am Coll Cardiol (2013) 0.96
Effect of ezetimibe monotherapy on the concentration of lipoprotein subfractions in patients with primary dyslipidaemia. Curr Med Res Opin (2007) 0.96
An ischemia detection method based on artificial neural networks. Artif Intell Med (2002) 0.96
Influence of smoking on predictors of vascular disease. Angiology (2003) 0.96
Clinical and laboratory characteristics of hypernatraemia in an internal medicine clinic. Nephrol Dial Transplant (2007) 0.96
Changes in vascular function and structure in juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) (2011) 0.95
Predictors of endothelial dysfunction in young women with polycystic ovary syndrome. J Clin Endocrinol Metab (2005) 0.95
Plasma lipoproteins and triacylglycerol are predictors of small, dense LDL particles. Lipids (2007) 0.94
Do statins beneficially or adversely affect glucose homeostasis? Curr Vasc Pharmacol (2010) 0.94
Benchmarking is associated with improved quality of care in type 2 diabetes: the OPTIMISE randomized, controlled trial. Diabetes Care (2013) 0.93
Massive haemothorax due to subclavian artery rupture: emergency thoracotomy or primary stent-grafting? Heart Lung Circ (2009) 0.93
Lack of association between carotid intima-media thickness and PAF-acetylhydrolase mass and activity in patients with primary hyperlipidemia. Angiology (2005) 0.93
Atorvastatin preferentially reduces LDL-associated platelet-activating factor acetylhydrolase activity in dyslipidemias of type IIA and type IIB. Arterioscler Thromb Vasc Biol (2002) 0.93
Treatment of hyperlipidaemia with fenofibrate and related fibrates. Expert Opin Investig Drugs (2008) 0.92
A 12-week, prospective, open-label analysis of the effect of rosuvastatin on triglyceride-rich lipoprotein metabolism in patients with primary dyslipidemia. Clin Ther (2007) 0.92
Early treatment reduces the cardiovascular risk factors in newly diagnosed rheumatoid arthritis patients. Semin Arthritis Rheum (2008) 0.92
Pharmacologically-induced metabolic acidosis: a review. Drug Saf (2010) 0.92
Native valve endocarditis due to Micrococcus luteus: a case report and review of the literature. J Med Case Rep (2011) 0.91
Hyponatremia in patients with infectious diseases. J Infect (2011) 0.91
Disturbances of phosphate metabolism: another feature of metabolic syndrome. Am J Kidney Dis (2005) 0.91
The hypertriglyceridemic waist phenotype is a predictor of elevated levels of small, dense LDL cholesterol. Lipids (2006) 0.91
Correction of anemia with erythropoietin in chronic kidney disease (stage 3 or 4): effects on cardiac performance. Cardiovasc Drugs Ther (2007) 0.91
"European panel on low density lipoprotein (LDL) subclasses": a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses: executive summary. Curr Vasc Pharmacol (2011) 0.90
The relationship of vitamin D with non-traditional risk factors for cardiovascular disease in subjects with metabolic syndrome. Arch Med Sci (2012) 0.89
Optimal type 2 diabetes mellitus management: the randomised controlled OPTIMISE benchmarking study: baseline results from six European countries. Eur J Prev Cardiol (2012) 0.89
Statins and renal function in patients with diabetes mellitus. Curr Med Res Opin (2003) 0.89
Effects of pioglitazone and metformin on vascular endothelial function in patients with type 2 diabetes treated with sulfonylureas. Diab Vasc Dis Res (2011) 0.89
Persistent erythema multiforme in a patient with extrahepatic cholangiocarcinoma. Oncology (2008) 0.89
The role of C-reactive protein in atherosclerotic cardiovascular disease: an overview. Curr Vasc Pharmacol (2008) 0.89
Association between serum gamma-glutamyltransferase and acute ischemic nonembolic stroke in elderly subjects. Arch Med Res (2009) 0.89
Effect of HMG-CoA reductase inhibitors on vascular cell apoptosis: beneficial or detrimental? Atherosclerosis (2009) 0.89